Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947347 · ClinicalTrials.gov registry record · Phase 3
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
A Phase 3 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT02947347 is a Phase 3 study that has completed, run by Pharmacyclics. The registered enrollment target is 445 participants.
The verdict
NCT02947347, a Phase 3 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).
Interventions
- DRUG Placebo
- DRUG Rituximab
- DRUG Ibrutinib Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947347
The ClinicalTrials.gov registry entry for NCT02947347 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02947347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947347 about?
NCT02947347 is a clinical study titled "Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma". This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).
What is the current status of trial NCT02947347?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2017-01-23. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT02947347?
The interventions under investigation include: Placebo (DRUG), Rituximab (DRUG), Ibrutinib Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT02947347?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.